We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Publicly Lists Healthcare Business

By Sanjit Dutt
Posted on 14 Nov 2016
Siemens AG (Munich, Germany), Europe’s largest industrial conglomerate, has announced that its USD 15 billion healthcare division, which operates under the uniform brand name Siemens Healthineers (Erlangen, Germany), will be publicly listed as an independent medical technology business.

In May 2014, Siemens had announced its intention to set up its healthcare business as a "company within the company" so that the business could adjust to transformations in the healthcare market in a flexible and focused manner with its own market presence. Siemens Healthineers focuses on the therapeutic and molecular diagnostic market, and offers medical imaging, laboratory diagnostics, and management, consulting and digital services. It is currently working with Pfizer to develop in vitro diagnostic tests for improving patient selection, treatment monitoring and dosing in clinical trials, as well as with ViiV Healthcare for developing diagnostics for its first-in-class HIV drug Celsentri (maraviroc).

Siemens has not yet provided any details about the planned scope and timing regarding the initial public offering of its healthcare business, but expects the move to encourage investors and provide a foundation for any future acquisitions or investments. "Healthcare technology is a highly attractive business in which we want to further expand our leading position. With this step, we continue to implement Vision 2020 launched in May 2014. The public listing will give Healthineers even more focus and flexibility in pursuing its growth strategy," said Joe Kaeser, President and CEO of Siemens AG. "The public listing is now the next step in further strengthening Siemens Healthineers in Siemens for the future. We're implementing this from an already leading position. Siemens Healthineers has already increased its market share and has an outstanding portfolio of top technologies that we're further developing," added Kaeser.

"The public listing is a key lever for reaching our strategic goal of being THE enabler for healthcare providers worldwide," said Bernd Montag, CEO of Siemens Healthineers. "Greater entrepreneurial freedom and agility will allow us to help shape the development of the global healthcare market and the growth strategies of successful healthcare providers. We'll enable our customers to participate successfully in the trends toward consolidation, industrialization and holistic health management with a high degree of clinical relevance, efficient workflows and financial value added."

Related Links:
Siemens
Siemens Healthineers

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Latest Industry News

Qiagen Acquires NGS Analysis Software Company Genoox

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels